Genomize’s SEQ Platform and Oxford Nanopore Technologies Come Together to Expand Access to Advanced Information-Rich Sequencing and Genomic Insights
Istanbul, Turkey – [April 07], 2026 – Genomize, a leader in high-end digital solutions for bioinformatics analysis of next-generation sequencing (NGS) data, today announced a new collaborative partnership with Oxford Nanopore Technologies through the Oxford Nanopore Compatible Products Programme. This strategic partnership recognizes Genomize’s SEQ Platform as an officially compatible product for analyzing data from Oxford Nanopore’s molecular sensing technology.
The Oxford Nanopore Compatible Products Programme brings organizations together to support interoperable products, services, and software solutions that enhance workflows using Oxford Nanopore’s technology. Through this collaboration, researchers and clinicians worldwide can seamlessly integrate Genomize’s advanced variant annotation and analysis capabilities with Oxford Nanopore’s rapid, information-rich sequencing platform, enabling deeper and more actionable insights.
Genomize’s cloud-based, CE-IVD-certified SEQ Platform supports whole-genome and whole-exome sequencing analyses for germline and somatic variants. When combined with Oxford Nanopore’s sequencing capabilities, this integrated workflow enables comprehensive analysis of structural variants, copy number variations, and complex genomic regions, delivering a more complete and clinically actionable view of the genome to support confident decision-making and accelerate research.
“We are excited to work closely with Oxford Nanopore Technologies to bring our complementary strengths together,” said Dr. Erşen Kavak, CEO of Genomize. “By aligning our bioinformatics expertise with their innovative sequencing technology, we are creating a shared ecosystem that empowers researchers and clinicians to generate more meaningful genomic insights.”
With its proprietary Variant Prioritization algorithm, the SEQ Platform enables users to perform Oxford Nanopore genomic analyses with a 97% successful prioritization rate. Its advanced CNV analysis capabilities, offering 96% sensitivity and 99% specificity, combined with Oxford Nanopore’s strength in detecting structural variants and phasing information, work together to deliver an unprecedented depth of genomic insight.
Key benefits of this partnership include:
- Seamless Integration: The SEQ Platform is optimized to process and analyze data from
- Oxford Nanopore sequencing devices, including MinION, GridION, and PromethION Oxford Nanopore Analysis Excellence: Enhanced capabilities for analyzing structural variants, copy number variations, and complex genomic regions that are challenging with short-read technologies
- Clinical-Grade Compliance: HIPAA and GDPR-compliant analysis platform with CE-IVD certification for clinical applications
- Rapid Results: Cloud-based infrastructure enabling fast variant annotation and interpretation of long-read sequencing data
- Comprehensive Reporting: Customizable, multilingual reporting system designed for both research and clinical settings
“Our collaboration with Genomize brings together Oxford Nanopore’s information- rich, rapid, and accessible molecular sensing platform with a powerful, clinically compliant analysis solution,” said Gordon Sanghera, CEO of Oxford Nanopore Technologies. “By optimising the processing of long-read data, we are enabling laboratories to translate complex genomic information into actionable insights with greater speed and confidence.”
The SEQ Platform has been successfully implemented in more than 450 hospitals and laboratories across 30+ countries, contributing to the diagnosis of hundreds of thousands of patients. This new partnership with Oxford Nanopore Technologies will further expand access to cutting-edge genomic analysis, particularly for applications requiring long-read sequencing such as structural variant detection, phasing, repeat expansion analysis, and complex genomic rearrangements.
Genomize will showcase the integrated SEQ Platform and Oxford Nanopore Technologies workflow at upcoming scientific conferences, and will offer demonstrations to interested researchers and clinicians.
About Genomize
Genomize develops high-end digital solutions for bioinformatics analysis of NGS data. Since 2014, the company has supported researchers and clinicians with accurate, efficient, and accessible tools for genomic interpretation. The SEQ Platform is a cloud-based, CE-IVD-certified, GDPR-compliant variant annotation solution designed for fast and reliable diagnostics.
For more, visit: https://genomize.com/
About Oxford Nanopore Technologies
Oxford Nanopore Technologies’ goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible and scalable analysis of DNA and RNA. The technology is used in more than 120 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes.
For more, visit: https://nanoporetech.com/
Media Contacts
Genomize
Ahmet Can Turkoglu – Director of Growth & Marketing
ahmetcan@genomize.com
Oxford Nanopore Technologies
media@nanoporetech.com
Related Links
1. Genomize SEQ Platform: https://seq.genomize.com/
2. Oxford Nanopore Compatible Products Programme:
https://nanoporetech.com/about/partners/nanopore-compatible-products-programme
3. Genomize Website: https://genomize.com/
4. Oxford Nanopore Technologies: https://nanoporetech.com/
